Matt Larew
Stock Analyst at William Blair
(0.02)
# 3,351
Out of 4,423 analysts
9
Total ratings
16.67%
Success rate
-46.41%
Average return
Main Sectors:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATR AptarGroup | Upgrades: Outperform | n/a | $149.08 | - | 1 | Apr 29, 2024 | |
| TECH Bio-Techne | Initiates: Outperform | n/a | $79.63 | - | 1 | Aug 28, 2023 | |
| AVTR Avantor | Downgrades: Market Perform | n/a | $24.77 | - | 1 | Jul 31, 2023 | |
| DNA Ginkgo Bioworks Holdings | Downgrades: Market Perform | n/a | $0.92 | - | 2 | May 11, 2023 | |
| INNV InnovAge Holding | Downgrades: Market Perform | n/a | $4.33 | - | 2 | Sep 22, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $4.73 | - | 1 | Aug 24, 2021 | |
| TWST Twist Bioscience | Initiates: Outperform | n/a | $43.20 | - | 1 | Jun 29, 2021 |
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $149.08
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $79.63
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $24.77
Upside: -
Ginkgo Bioworks Holdings
May 11, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.92
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $4.33
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.73
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $43.20
Upside: -